Azalide Compounds for Immune Modulation Without Antibacterial Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for non-antibacterial, anti-inflammatory and immune-modulating agents to control or prevent inflammatory responses in animals, particularly in bovine respiratory disease (BRD), which are not associated with the antibacterial effects of traditional macrolides, to reduce antibiotic use and mitigate inflammatory diseases.
Innovation Solution
Development of 13-membered and 15-membered macrolide ring compounds, known as azalides, which are in equilibrium, and their stereoisomers and pharmaceutically acceptable salts, to modulate immune responses and reduce inflammation without antibacterial activity, administered in compositions with carriers to treat inflammatory responses in animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional macrolide antibiotics are used to treat respiratory infections, then antibacterial activity is improved, but immune-modulating activity is insufficient and antibiotic resistance increases
Solution Approach 1:
The patent extracts and isolates the immune-modulating properties from the antibacterial properties of macrolides by modifying the chemical structure to remove the C9 methyl group, creating compounds that selectively retain anti-inflammatory and immune-modulating activities while eliminating antibacterial effects. This resolves the contradiction by separating the two functions that were previously coupled in traditional macrolides.
Solution Approach 2:
The patent applies parameter changes by modifying specific chemical parameters of the macrolide structure (removing C9 methyl group, adjusting substituents at positions 6, 11, and 13) to transform the compound's biological profile from antibacterial to non-antibacterial while enhancing immune-modulating activity. This structural parameter modification resolves the contradiction between maintaining therapeutic efficacy and eliminating antibiotic resistance.
2Object-affected harmful factors
If macrolide antibiotics are used to control inflammatory responses, then anti-inflammatory benefits are achieved, but antibacterial effects are maintained which contributes to resistance
Solution Approach 1:
The patent converts the harmful effect of antibiotic overuse (resistance development) into a beneficial outcome by designing compounds that deliberately lack antibacterial activity. The 'harm' of removing antibacterial function is transformed into the 'benefit' of eliminating resistance pressure while preserving and enhancing immune-modulating therapy for inflammatory conditions.
3Object-affected harmful factors
If higher dosages of traditional macrolides are used to achieve immune-modulating effects, then anti-inflammatory activity is improved, but antibacterial effects increase contributing to resistance
Solution Approach 1:
The patent extracts the immune-modulating function from the antibacterial function, allowing the compound to achieve therapeutic immune modulation at lower dosages without the confounding antibacterial effect. This separation enables precise control of immune response modulation while minimizing antibiotic exposure and resistance risk.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Defined herein are immunomodulating Formula (1) compounds, wherein R, R0, R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating or preventing an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof; or use of said Formula (1) compound to prepare a medicament for treating or preventing an inflammatory and/or immunological disease or disorder in an animal.